外周血miR-181a与PGRMC1水平与乳腺癌特征相关性研究

doi:10.3969/j.issn.1006-7795.2026.04.008

首都医科大学学报

• 更年期妇科内分泌与生育力保护 • 上一篇下一篇

外周血miR-181a与PGRMC1水平与乳腺癌特征相关性研究

王月姣¹,阮祥燕^1,2*,谷牧青¹,魏芸³,管煜伟³,Alfred O.Mueck^1.2

1.首都医科大学附属北京妇产医院/北京妇幼保健院内分泌科，北京 100026；2.德国图宾根大学妇产医院妇女健康部与妇女健康研究中心，图宾根 D-72076；3.北京化工大学化工资源有效利用国家重点实验室，北京 100029

收稿日期:2026-04-09 修回日期:2026-05-30 出版日期:2026-08-21 发布日期:2026-06-30
通讯作者: 阮祥燕 E-mail:ruanxiangyan@ccmu.edu.cn
基金资助:
生命谷临床成果转化概念验证计划（SMGPOC01020）,北京市科技新星计划资助(20230484438),北京市博士后工作经费科研活动资助（368456）。

Study on the correlation between blood miR-181a and PGRMC1 levels and breast cancer characteristics

Wang Yuejiao¹ , Ruan Xiangyan^1，2*, Gu Muqing¹, Wei Yun³, Guan Yuwei³, Alfred O.Mueck^1，2

1.Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care Hospital, Beijing 100026, China;2.Department of Women's Health, Research Centre for Women's Health and University Women's Hospital of Tuebingen, University Hospitals of Tuebingen, Tuebingen D-72076, Germany;3.State key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, China

Received:2026-04-09 Revised:2026-05-30 Online:2026-08-21 Published:2026-06-30
Supported by:
This study was supported by Life Valley Clinical Transformation and Technology Validation Program （SMGPOC01020）,Beijing Nova Program (20230484438)， Beijing Postdoctoral Research Fund (368456).

摘要/Abstract

摘要：

目的探讨血清微小RNA-181a（microRNA-181a，miR-181a）与全血孕激素受体膜组分1（progesterone receptor membrane component 1 ,PGRMC1）的表达水平与乳腺癌临床特征的相关性，并评估二者作为乳腺癌风险潜在生物标志物的可能性。方法募集并收集60例术前乳腺癌患者（病例组）和60例年龄匹配的健康女性（对照组）的血液样本。采用实时荧光聚合酶链式反应（real-time fluorescence polymerase chain reaction，RT-qPCR）和酶联免疫吸附试验（enzyme-linked immunosorbent assay，ELISA）检测血清miR-181a-5p的相对表达量及全血PGRMC1浓度。分析两组间miR-181a与PGRMC1水平相关性及比较不同临床病理特征亚组间的差异。结果与健康对照组相比，乳腺癌患者血清miR-181a表达水平显著降低（P<0.001），而PGRMC1浓度显著升高（P<0.001）。在乳腺癌患者中，血清miR-181a水平与PGRMC1浓度呈显著负相关（P<0.01）。组间比较显示，肿瘤直径T3-T4组、临床分期Ⅲ-Ⅳ级、淋巴结转移与肿瘤直径T1-T2、临床分期Ⅰ-Ⅱ、淋巴结无转移相比，血清miR-181a相对表达较低，PGRMC1浓度较高（均P<0.05）。结论乳腺癌患者血清中miR-181a表达下调，PGRMC1蛋白水平上调，二者呈负相关，血清miR-181a低表达和PGRMC1高表达与肿瘤直径大、组织学分级高、淋巴结转移及临床分期晚等提示肿瘤侵袭性强和预后差的病理特征密切相关，提示联合检测血清miR-181a和PGRMC1可能为乳腺癌的风险预测提供新的思路。

关键词: 绝经激素治疗, 孕激素, 乳腺癌, 微小RNA-181a, 孕激素受体膜组分1, 血清生物标志物, 病例对照研究

Abstract: ObjectiveTo investigate the correlation between the expression of microRNA-181a (miR-181a) in serum and the progesterone receptor membrane component 1 (PGRMC1) in whole blood, as well as the association with breast cancer characteristics, and to evaluate its potential as a biomarker for breast cancer risk.MethodsBlood samples were collected from 60 pre-operative breast cancer patients and 60 age-matched healthy women. The relative expression level of serum miR-181a and the concentration of PGRMC1 in whole blood were measured using real-time fluorescence polymerase chain reaction （RT-qPCR） and enzyme-linked immunosorbent assay （ELISA), respectively. The correlation between miR-181a and PGRMC1 levels was analyzed in both groups, with further comparisons made among subgroups based on clinicopathological characteristics.ResultsCompared with the healthy control group, the serum miR-181a expression level was significantly decreased in breast cancer patients (P < 0.001), while the PGRMC1 concentration was significantly increased (P < 0.001). Among breast cancer patients, serum miR-181a levels were significantly negatively correlated with PGRMC1 concentrations (P < 0.01). Intergroup comparisons showed that the T3-T4 tumor diameter group, clinical stage Ⅲ-Ⅳ group, and lymph node metastasis group had lower serum miR-181a relative expression and higher PGRMC1 concentrations compared to the T1-T2 tumor diameter group, clinical stage Ⅰ-Ⅱ group, and lymph node non-metastasis group, respectively (all P < 0.05).ConclusionThe expression of miR-181a in the serum of breast cancer patients is downregulated, and the protein level of PGRMC1 is upregulated. They are negatively correlated and closely related to the malignant characteristics of breast cancer, suggesting that the combined detection of serum miR-181a and PGRMC1 may provide a new perspective on risk assessment and prognosis of breast cancer.

Key words: menopausal hormone therapy, progestin , breast cancer, microRNA-181a, progesterone receptor membrane component 1, serum biomarker； case control study

中图分类号:

R737.9

王月姣, 阮祥燕, 谷牧青, 魏芸, 管煜伟, Alfred O.Mueck. 外周血miR-181a与PGRMC1水平与乳腺癌特征相关性研究[J]. 首都医科大学学报, doi: 10.3969/j.issn.1006-7795.2026.04.008.

Wang Yuejiao , Ruan Xiangyan, Gu Muqing, Wei Yun, Guan Yuwei, Alfred O.Mueck, . Study on the correlation between blood miR-181a and PGRMC1 levels and breast cancer characteristics[J]. Journal of Capital Medical University, doi: 10.3969/j.issn.1006-7795.2026.04.008.

参考文献

［1］Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71(3): 209－249.
［2］李全美, 邹燕. 1990-2021年中国育龄期女性常见恶性肿瘤发病与死亡趋势及预测分析［J］. 中华肿瘤防治杂志, 2026, 33 (1): 1-7.
［3］盛燕, 李晨阳,高丽娜,等. 1990-2021年中国年轻女性乳腺癌疾病负担及危险因素趋势分析［J］. 中华肿瘤防治杂志, 2025, 32 (18): 1107-1113.
［4］卑佳怡, 陈波. 基于新一代测序技术的乳腺癌精准诊疗策略与耐药机制研究［J］. 中国医科大学学报, 2026, 55 (3): 193-197.
［5］潘小锋, 周玮,方芳. 基于公共数据库识别与乳腺癌发生发展及预后的相关基因［J］. 兰州大学学报(医学版), 2022, 48 (4): 23-29.
［6］Mahboobnia K, Beveridge D J, Yeoh G C, et al. MicroRNAs in hepatocellular carcinoma pathogenesis: insights into mechanisms and therapeutic opportunities［J］. Int J Mol Sci, 2024, 25(17): 9393.
［7］Chen J B, Liu K, Vadas M A. The role of the MiR-181 family in hepatocellular carcinoma［J］. Cells, 2024, 13(15): 1289.
［8］Gu M Q, Wang L J, Yang C, et al. Micro-RNA-181a suppresses progestin-promoted breast cancer cell growth［J］. Maturitas, 2018, 114: 60－66.
［9］Cai G J, Wang Y J, Houda T, et al. MicroRNA-181a suppresses norethisterone-promoted tumorigenesis of breast epithelial MCF10A cells through the PGRMC1/EGFR-PI3K/Akt/mTOR signaling pathway［J］. Transl Oncol, 2021, 14(6): 101068.
［10］Ruan X Y, Mueck A O. Clinical importance of PGRMC1 in hormone responsive breast cancer［J］. Breast Care, 2023, 18(3): 172－178.
［11］Ruan X, Neubauer H, Yang Y, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells［J］. Climacteric, 2012, 15(5): 467－472.
［12］Zhang Y, Ruan X Y, Willibald M, et al. May progesterone receptor membrane component 1(PGRMC1) predict the risk of breast cancer?［J］. Gynecol Endocrinol, 2016, 32(1): 58－60.
［13］Zhao Y, Ruan X, Cheng J, et al. PGRMC1 promotes triple-negative breast cancer cell growth via suppressing ferroptosis［J］. Climacteric, 2023, 26(2): 135－142.
［14］赵越, 阮祥燕, 程姣姣, 等. 乳腺癌中PGRMC1表达与临床病理参数的相关性［J］. 首都医科大学学报, 2022, 43(3): 350－356.
［15］Nicholls R J, Zinicola R, Haboubi N. Extramural spread of rectal cancer and the AJCC Cancer Staging Manual 8th edition, 2017［J］. Ann Oncol, 2019,30(8):1394－1395.
［16］王月姣, 阮祥燕, 谷牧青, 等. PGRMC1: 绝经激素治疗中乳腺癌风险预测的潜在生物学标志物［J］. 首都医科大学学报, 2025, 46(4): 589－593.
［17］Zhang Y W, Guan Y P, Zheng X Y, et al. Hypoxia-induced miR-181a-5p up-regulation reduces epirubicin sensitivity in breast cancer cells through inhibiting EPDR1/TRPC1 to activate PI3K/AKT signaling pathway［J］. BMC Cancer, 2024, 24(1): 167.
［18］Wang Y, Tahiri H, Yang C, et al. Overexpression of miR-181a regulates the Warburg effect in triple-negative breast cancer［J］. Climacteric, 2023, 26(1): 64－71.
［19］赵越, 阮祥燕, 谷牧青, 等. PGRMC1在激素治疗中促进乳腺癌细胞增殖的机制研究［J］. 中国癌症防治杂志, 2022, 14(4): 378－384.

[1]	赵越, 阮祥燕, 王月姣, 谢丹, 金婧, 田玄玄, 张煦, 张娥, 朱建国, 张政. 多囊卵巢综合征患者关键调控分子表达与代谢紊乱的相关性研究[J]. 首都医科大学学报, 2026, 47(4): 643-649.
[2]	李情, 王嗣淇, 马天宇, 马枭琪, 孙雨婷, 滕旭, 余和芬, 张竞尧, 黄蔚. 组蛋白去乙酰化酶3促进三阴性乳腺癌细胞上皮－间充质转化的作用和机制研究[J]. 首都医科大学学报, 2026, 47(4): 738-753.
[3]	刘真真, 刘炜霄, 谢萍. 细胞骨架调节蛋白RACGAP1参与CDK4/6抑制剂耐药性治疗的机制探究[J]. 首都医科大学学报, 2026, 47(2): 240-250.
[4]	王月姣, 阮祥燕, 谷牧青, 魏芸, 管煜伟, 赵越, Alfred O.Mueck. PGRMC1：绝经激素治疗中乳腺癌风险预测的潜在生物学标志物[J]. 首都医科大学学报, 2025, 46(4): 589-593.
[5]	徐晶星, 周全, 应建明. 肿瘤微环境在三阴性乳腺癌免疫治疗中的研究进展[J]. 首都医科大学学报, 2023, 44(5): 882-888.
[6]	杨一凡, 王雅梅. 凋亡诱导因子2在乳腺癌中的表达及其相关作用[J]. 首都医科大学学报, 2023, 44(2): 248-257.
[7]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[8]	高明, 周营利, 朱研, 秦君平, 黄惠斌, 任昱, 谈莉, 周华, 许媛. 重症患者急性期能量平衡对住院期间死亡的影响[J]. 首都医科大学学报, 2021, 42(6): 931-935.
[9]	魏常胜, 骆成玉, 张树琦. 环乳晕切口联合乳腔镜腋窝淋巴结清扫在早期乳腺癌保乳手术中的应用[J]. 首都医科大学学报, 2021, 42(6): 1014-1020.
[10]	中华预防医学会妇女保健分会; 中国人体健康科技促进会妇科内分泌与生育力促进专委会. 乳腺癌患者选择性雌激素受体调节剂治疗相关子宫内膜安全管理的中国专家共识(2021版)[J]. 首都医科大学学报, 2021, 42(4): 672-677.
[11]	阮祥燕, 杨瑜, 卢丹, 杜娟, 程姣姣, 谷牧青, 李扬璐, 金凤羽, 段微, 代荫梅, 鞠蕊, 许新, MatthiasKorell, AlfredO.Mueck. 中国首例乳腺癌患者冻存卵巢组织移植成功报道及文献复习[J]. 首都医科大学学报, 2021, 42(2): 177-182.
[12]	杨阳, 康骅, 赵菁, 凌煜玮, 赵烨, 王亚军, 戎冬冬. 术前乳腺MRI对乳腺癌保乳手术切缘评估的回顾性分析[J]. 首都医科大学学报, 2020, 41(6): 943-953.
[13]	王爱婷, 鄢丹, 齐宪荣. 包载多西他赛的聚合物胶束抑制小鼠乳腺癌转移作用研究[J]. 首都医科大学学报, 2020, 41(2): 225-230.
[14]	王维, 张紫寒, 翟妍, 桑翠琴, 王淑珍. 子宫体、乳腺双原发癌的临床病理特征[J]. 首都医科大学学报, 2019, 40(6): 857-862.
[15]	张蕴显, 王雅梅, 周萍. 乳腺癌中基于开放染色质的环状RNA互作网络构建及功能分析[J]. 首都医科大学学报, 2019, 40(6): 901-910.

外周血miR-181a与PGRMC1水平与乳腺癌特征相关性研究

Study on the correlation between blood miR-181a and PGRMC1 levels and breast cancer characteristics

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价